ETWC Etrials Worldwide (MM)

etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical software and services that optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, announced today that Phenomix Corporation has selected etrials� Trial Intelligence electronic data capture (EDC) and reporting solution as the central component of its clinical data management process, playing a key role in helping Phenomix to glean actionable information from its clinical trial data, thereby enhancing and accelerating decision-making.

Phenomix, a biopharmaceutical company headquartered in San Diego, develops treatments for Type 2 diabetes and hepatitis C virus or HCV infection, and is focused on the discovery, development and commercialization of novel small-molecule product candidates. Phenomix�s internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development.

"The quality of data and the ability to complete a thorough data analysis are critical success factors for any clinical study. etrials� Trial Intelligence EDC solution affords us rapid and accurate data collection, and offers the ability to integrate pertinent IVR data into EDC in real-time," said Hans-Peter Guler, M.D., chief medical officer at Phenomix Corporation. "Every opportunity to reduce cycle time moves us that much closer to bringing an important new therapy to market. As such, etrials provides an important resource which will aid us in our mission to help patients who are battling Type 2 diabetes.�

After a formal evaluation of several EDC vendors, the Phenomix team felt the etrials Trial Intelligence EDC solution would offer its team the broadest functionality with advanced, flexible reporting capabilities through a user-friendly, intuitive interface with built-in workflows. Phenomix is also leveraging etrials to integrate its IVRS system with the etrials EDC system in an effort to maximize the value of its current and future technology investments.

"Our eClinical solutions deliver significant time and costs savings with greater access to actionable information faster," said M. Denis Connaghan, CEO and president of etrials. "We are proud to be involved in Phenomix�s efforts to develop these treatments. Phenomix�s selection of etrials� Trial Intelligence Solution speaks not only to our ongoing dedication to product innovation and customer support, but also to our mission of helping sponsors attain operational excellence in clinical research.�

About Phenomix Corporation

Phenomix is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule product candidates directed toward clinically validated targets in significant therapeutic markets. The company�s lead product candidate, dutogliptin (PHX1149), is a dipeptidyl-peptidase-4, or DPP-4, inhibitor in Phase 3 development as an oral, once-daily treatment for Type 2 diabetes. Phenomix has a collaboration with Forest Laboratories to develop and commercialize dutogliptin in North America. The company�s second product candidate, PHX1766, is a protease inhibitor in Phase 1 clinical development for the treatment of hepatitis C virus, or HCV, infection. Phenomix is based in San Diego, California. For more information, visit www.phenomix.com.

About etrials(R)

etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of eClinical software and services to pharmaceutical, biotechnology, medical device and contract research organizations, offers adaptive, Web-based tools that work together to coordinate data capture, logistics, patient interaction and trial management � turning data into intelligence and shortening the pathway to an actionable study endpoint. etrials is one of the only top-tier solution providers that offers electronic data capture (EDC), interactive voice and Web response (IVR/IWR), electronic patient diaries (eDiary) as part of a flexible and integrated software-as-a-service (SaaS) platform or as individual solutions to capture high quality data from multiple pivot points to enable real-time access for perfectly informed decision-making. As an experienced leader, etrials has facilitated over 900 trials involving more than 450,000 patients in 70 countries, and has participated in 42 studies that resulted in 14 approved new drug applications and/or regulatory approvals. To learn more visit us at www.etrials.com. etwcf

Forward-Looking Statements

This announcement may contain forward-looking statements, including statements regarding the size, number of sites and patients, new projects, modifications to existing projects, and duration of clinical trial projects awarded to the Company. These statements involve risks and uncertainties. Actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to, the need to finalize definitive agreements for the awards, delays in the current schedule for clinical trials by the client, utilization of our software and services by clients to a lesser degree than is currently expected and early termination of the projects, all of which are possible because our agreements do not generally have minimum volume guarantees and can be terminated without penalty by clients. More information about potential factors which could cause actual results to differ from the forward-looking statements included in this announcement is included in our filings with the Securities and Exchange Commission, including the "Risk Factors" Section of the Form 10-Q filed on November 12, 2008. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update such statements.

etrials� is the registered trademark in the United States of etrials Worldwide, Inc. Other marks belong to their respective owners and are used with permission.

Etrials Worldwide (MM) (NASDAQ:ETWC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Etrials Worldwide (MM) (NASDAQ:ETWC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024